HRP20240585T1 - Postupci uzgoja stanica - Google Patents

Postupci uzgoja stanica Download PDF

Info

Publication number
HRP20240585T1
HRP20240585T1 HRP20240585TT HRP20240585T HRP20240585T1 HR P20240585 T1 HRP20240585 T1 HR P20240585T1 HR P20240585T T HRP20240585T T HR P20240585TT HR P20240585 T HRP20240585 T HR P20240585T HR P20240585 T1 HRP20240585 T1 HR P20240585T1
Authority
HR
Croatia
Prior art keywords
recombinant protein
total amount
seq
production phase
cells
Prior art date
Application number
HRP20240585TT
Other languages
English (en)
Croatian (hr)
Inventor
Bassem BEN YAHIA
Laetitia Malphettes
Nadine KOCHANOWSKI
Gill RENNER
Sandrine DURRAN
Andrew Jeffrey Yates
Original Assignee
UCB Biopharma SRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=59270991&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20240585(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by UCB Biopharma SRL filed Critical UCB Biopharma SRL
Publication of HRP20240585T1 publication Critical patent/HRP20240585T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0018—Culture media for cell or tissue culture
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/32—Amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2511/00—Cells for large scale production
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2523/00—Culture process characterised by temperature

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Analytical Chemistry (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
HRP20240585TT 2017-05-31 2018-05-29 Postupci uzgoja stanica HRP20240585T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1708655.4A GB201708655D0 (en) 2017-05-31 2017-05-31 Cell culture methods
PCT/EP2018/064102 WO2018219968A1 (en) 2017-05-31 2018-05-29 Cell culture methods
EP18743683.7A EP3630946B1 (en) 2017-05-31 2018-05-29 Cell culture methods

Publications (1)

Publication Number Publication Date
HRP20240585T1 true HRP20240585T1 (hr) 2024-07-19

Family

ID=59270991

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20240585TT HRP20240585T1 (hr) 2017-05-31 2018-05-29 Postupci uzgoja stanica

Country Status (21)

Country Link
US (3) US12077796B2 (enExample)
EP (2) EP4397682A3 (enExample)
JP (3) JP7460370B2 (enExample)
KR (3) KR20240096888A (enExample)
CN (2) CN119326882A (enExample)
AU (2) AU2018276376C1 (enExample)
BR (1) BR112019024390A2 (enExample)
CA (1) CA3065661A1 (enExample)
CL (1) CL2019003459A1 (enExample)
CO (1) CO2019012871A2 (enExample)
EA (1) EA201992828A1 (enExample)
ES (1) ES2978394T3 (enExample)
GB (1) GB201708655D0 (enExample)
HR (1) HRP20240585T1 (enExample)
HU (1) HUE066922T2 (enExample)
IL (2) IL317828A (enExample)
MX (1) MX2019014140A (enExample)
MY (1) MY193535A (enExample)
PL (1) PL3630946T3 (enExample)
RU (2) RU2758674C2 (enExample)
WO (1) WO2018219968A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201708655D0 (en) * 2017-05-31 2017-07-12 Ucb Biopharma Sprl Cell culture methods
JP2023554489A (ja) * 2020-12-22 2023-12-27 ノバルティス アーゲー 細胞培養中の分泌された組換え発現タンパク質中のシステイン残基の酸化レベルを低減するための方法
GB202105424D0 (en) 2021-04-16 2021-06-02 UCB Biopharma SRL Cell culture processes

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5672502A (en) 1985-06-28 1997-09-30 Celltech Therapeutics Limited Animal cell culture
US6048728A (en) 1988-09-23 2000-04-11 Chiron Corporation Cell culture medium for enhanced cell growth, culture longevity, and product expression
EP2218775B1 (en) 1996-08-30 2015-01-28 Life Technologies Corporation Method for producing a polypeptide in vitro in mammalian cells in a protein-free and serum-free culture medium
EP1441589B1 (en) 2001-11-08 2012-05-09 Abbott Biotherapeutics Corp. Stable liquid pharmaceutical formulation of igg antibodies
EP1623019B2 (en) 2003-05-15 2017-01-25 Wyeth LLC Restricted glucose feed for animal cell culture
TWI364458B (en) 2004-08-27 2012-05-21 Wyeth Res Ireland Ltd Production of tnfr-lg
TWI384069B (zh) 2004-08-27 2013-02-01 Pfizer Ireland Pharmaceuticals 多胜肽之製法
US7335491B2 (en) 2004-08-27 2008-02-26 Wyeth Research Ireland Limited Production of anti-abeta
CN104152395B (zh) * 2006-11-08 2020-03-10 惠氏公司 合理设计的细胞培养基
US8030027B2 (en) * 2008-04-29 2011-10-04 St. Jude Children's Research Hospital Method for enhancing recombinant antibody production
US8252557B2 (en) 2008-10-28 2012-08-28 Chugai Seiyaku Kabushiki Kaisha Peptide-containing culture medium for culturing animal cell
US20110262965A1 (en) 2010-04-23 2011-10-27 Life Technologies Corporation Cell culture medium comprising small peptides
CA2797140C (en) 2010-04-26 2018-01-23 Novartis Ag Improved cell culture medium
CN102858954A (zh) 2010-04-26 2013-01-02 诺瓦提斯公司 改进的细胞培养方法
CN102653729B (zh) 2011-03-04 2014-07-16 上海赛金生物医药有限公司 一种用于中国仓鼠卵巢细胞的培养基
US9133493B2 (en) * 2011-04-21 2015-09-15 Amgen Inc. Method for culturing mammalian cells to improve recombinant protein production
JP6265970B2 (ja) * 2012-03-26 2018-01-24 サノフイ 安定なＩｇＧ４に基づく結合剤の製剤
WO2013158275A1 (en) * 2012-04-20 2013-10-24 Abbvie Inc. Cell culture methods to reduce acidic species
US20130281355A1 (en) 2012-04-24 2013-10-24 Genentech, Inc. Cell culture compositions and methods for polypeptide production
GB201208370D0 (en) 2012-05-14 2012-06-27 Ucb Pharma Sa Antibodies
GB201208367D0 (en) * 2012-05-14 2012-06-27 Ucb Pharma Sa Biological product
JP2016513478A (ja) * 2013-03-15 2016-05-16 ジェネンテック， インコーポレイテッド 細胞培養培地及び抗体を産生する方法
KR102434588B1 (ko) 2014-06-18 2022-08-22 메디뮨 엘엘씨 N-아세틸시스테인을 포함하는 세포 배양 방법 및 배지
KR20170100074A (ko) 2014-12-29 2017-09-04 완롭 위롯페이싯 상승된 전압 및 향상된 장착 방식을 구비한 엔진 연소시스템의 산소효율 증진장치
GB201508180D0 (en) 2015-05-13 2015-06-24 Ucb Biopharma Sprl Antibodies
ES2967868T3 (es) 2016-04-28 2024-05-06 Merck Patent Gmbh Método para reducir el nivel de trisulfuro en proteínas
GB201608323D0 (en) 2016-05-12 2016-06-29 Ucb Biopharma Sprl Pharmaceutical compositions
WO2018018613A1 (zh) * 2016-07-29 2018-02-01 广东东阳光药业有限公司 一种提高抗体纯度的细胞培养基和培养方法
CN106222129A (zh) 2016-07-29 2016-12-14 广东东阳光药业有限公司 一种提高抗体纯度的细胞培养基和培养方法
GB201708655D0 (en) * 2017-05-31 2017-07-12 Ucb Biopharma Sprl Cell culture methods

Also Published As

Publication number Publication date
GB201708655D0 (en) 2017-07-12
AU2024259881A1 (en) 2024-11-28
RU2021128024A (ru) 2021-12-08
CN119326882A (zh) 2025-01-21
US20250066832A1 (en) 2025-02-27
EP3630946C0 (en) 2024-03-27
AU2018276376B2 (en) 2024-08-15
AU2018276376A1 (en) 2019-12-12
AU2024259881B2 (en) 2025-02-13
CN110741077A (zh) 2020-01-31
US20200239923A1 (en) 2020-07-30
JP2022153421A (ja) 2022-10-12
KR20200012972A (ko) 2020-02-05
BR112019024390A2 (pt) 2020-07-14
CO2019012871A2 (es) 2020-01-17
AU2018276376C1 (en) 2025-01-30
MY193535A (en) 2022-10-18
CA3065661A1 (en) 2018-12-06
EA201992828A1 (ru) 2020-04-21
IL317828A (en) 2025-02-01
HUE066922T2 (hu) 2024-09-28
IL270880A (en) 2020-01-30
JP2021185185A (ja) 2021-12-09
JP2020521490A (ja) 2020-07-27
WO2018219968A1 (en) 2018-12-06
EP4397682A2 (en) 2024-07-10
MX2019014140A (es) 2020-02-07
KR20250156183A (ko) 2025-10-31
EP3630946A1 (en) 2020-04-08
PL3630946T3 (pl) 2024-07-01
JP7406593B2 (ja) 2023-12-27
US12077796B2 (en) 2024-09-03
RU2019143742A3 (enExample) 2021-06-30
IL270880B1 (en) 2025-01-01
CL2019003459A1 (es) 2020-04-24
ES2978394T3 (es) 2024-09-11
CN110741077B (zh) 2024-10-11
IL270880B2 (en) 2025-05-01
JP7560420B2 (ja) 2024-10-02
EP3630946B1 (en) 2024-03-27
US20250051824A1 (en) 2025-02-13
JP7460370B2 (ja) 2024-04-02
KR20240096888A (ko) 2024-06-26
RU2758674C2 (ru) 2021-11-01
RU2019143742A (ru) 2021-06-30
EP4397682A3 (en) 2024-08-21

Similar Documents

Publication Publication Date Title
AR040046A1 (es) Anticuerpo neutralizante humano anti-igfr
JP2022177090A5 (enExample)
RU2012131671A (ru) Способ полипептидной модификации для очистки полипептидных мультимеров
HRP20231175T1 (hr) Postupci kultiviranja stanica
HRP20190932T1 (hr) Molekule protutijela koje se vežu na il-17a i il-17f
FI2155783T4 (fi) Lajien välisesti spesifinen cd3-epsilon-sitoutumisdomeeni
PE20211863A1 (es) Moleculas de union a antigeno biespecificas que comprenden el clon 212 anti-fap
HRP20130883T4 (hr) Međuvrsno specifična cd3-epsilon-vežuća domena
IL268620B1 (en) Antibodies against LAG3 pharmaceutical formulations containing them, and their uses for cancer treatment
HRP20191983T1 (hr) Konstrukti protutijela za cdh19 i cd3
RU2015144105A (ru) Антитела к гепсидину и их применения
HRP20211794T1 (hr) Humana antitijela za pd-1
RU2016129274A (ru) Канинизированные мышиные антитела к человеческому pd-1
HRP20240102T1 (hr) Monoklonsko protutijelo koje antagonizira i inhibira vezanje između humanog pd-1 antigena i njegovog liganda, postupak njegove priprave i primjena
AR110659A1 (es) Proteínas de unión a antígenos anti-neuropilin y método para su uso
HRP20251020T1 (hr) Proteini s jednolančanim varijabilnim fragmentom koji vežu cd3
HRP20120759T1 (hr) Bispecifična veziva specifična između vrsta
AR097651A1 (es) Métodos y composiciones que comprenden polipéptidos recombinantes purificados
JP2020537520A5 (enExample)
RU2010145063A (ru) Новые антитела, используемые для лечения рака
HRP20240585T1 (hr) Postupci uzgoja stanica
HRP20191277T1 (hr) Anti-cd26 antitijela i njihove primjene
HRP20192038T1 (hr) Protutijela receptora anti-epidermalnog faktora rasta (egfr)
AU2025204857A1 (en) Producing compositions comprising two or more antibodies
JP2020521490A5 (enExample)